Analyst Price Target Update on Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN): The mean short term price target for Agenus (NASDAQ:AGEN) has been established at $9.25 per share. The higher price target estimate is at $14 and the lower price target estimate is expected at $6 according to 4 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $3.59

Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Maxim Group upgrades its rating on Agenus (NASDAQ:AGEN). The rating major has initiated the coverage with buy rating on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The Analysts at Maxim Group announces a current price target of $7 per share. The rating by the firm was issued on March 11, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, Armen Garo H, CEO of Agenus Inc, had purchased 100,000 shares on May 6, 2016. The total value of the transaction was $318,000. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Agenus (NASDAQ:AGEN) witnessed a volatile trading activity on Monday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $3.97 and reached the intraday high at $4.11. The bulls started the profit booking and pushed the shares to intraday low of $3.91. The trading session was marked by a volume range of 872,595 shares exchanging hands. The 52-week high of the shares is $10.1599 and the 52-week low is $2.61. The market cap of the company stands at $348 million and there are 86,882,451 shares in public circulation.

Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *